Nanochon Performs First Case in the Chondrograft™ First in Human Clinical Study
Baltimore, MD, September 2, 2026 – Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the […]
Baltimore, MD, September 2, 2026 – Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the […]
August 14, 2026 – Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular
CAPITAL After the close of our Seed Prime II round in January, we received significant interest from follow-on investors, so
Dear Colleagues, Nanochon’s 10-year anniversary represents a time for us to reflect on the immense progress we’ve made over the
CAPITAL Following the formal close of our Seed Prime II round at $4.1M (pre-money valuation: $24M) announced in January, additional
Charlotte K Barton1, Kathryn Seabaugh 1, Ben Gadomski 2, Kevin Labus 2, Ben Holmes 3, Nathan Castro 3, Mike Hawes
Capital Nanochon has closed another oversubscribed round, bringing in new capital and increasing the total amount raised to $4.1M. This
This article was originally published on UVA Today This Alum’s Tech May Revolutionize Knee Joint Replacements Benjamin Holmes can pinpoint
WASHINGTON, January 12, 2026 — Nanochon, a Washington, DC-based orthopedic device company developing an implant for treating articular cartilage defects
Emilia Aram , David C. Flanigan, MD, Nathan J. Castro, PhD, Doug Snell, Luke Aram Purpose: Osteochondral defects can present